BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

AstraZeneca

AstraZeneca logo

Website
http://www.astrazeneca-us.com/
Founded
1999
Patents
111
Clinical Trials
2497
Publications
181

Technologies

Antisense Oligonucleotides

AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.

AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved.

Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.


Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

July 28, 2021  
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

News

  • 2025-04-28
    Tempus Introduces Loop, an AI-Driven Platform for Target Discovery and Validation
  • 2024-12-20
    Alphabet's AI Spinoff Raises $300M at $5.3B Valuation Amid Biopharma Partnerships

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.